 | Up a level |
Haas, M., Waldschmidt, D., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R. J. C., Malfertheiner, P., Illerhaus, G., Kubicka, S., Held, S., Westphalen, C. B., Kruger, S., Boeck, S. and Heinemann, V. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Ann. Oncol., 29. S. 243 - 244. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852